Table 3.
VEGF overexpression and clinicopathological features of NHL.
| Clinicopathological features | Number of studies | Number of patients | Analytical model | Pooled OR (95% CI) | P value | Heterogeneity | |
|---|---|---|---|---|---|---|---|
| I 2 (%) | P value | ||||||
| Performance status (ECOG) (0-1 versus ⩾ 2) |
4 | 502 | REM | 0.84 (0.39–1.88) | 0.64 | 67.8 | 0.025 |
| LDH level (normal versus elevated) |
4 | 502 | FEM | 0.98 (0.64–1.51) | 0.93 | 5 | 0.37 |
| IPI score (0–2 versus 3–5) |
4 | 383 | REM | 0.45 (0.15–1.39) | 0.17 | 78.3 | 0.003 |
| Tumor staging (I II versus III IV) |
5 | 483 | REM | 0.76 (0.36–1.57) | 0.45 | 62.4 | 0.03 |
| B symptom (absent versus present) |
5 | 547 | FEM | 0.96 (0.65–1.42) | 0.84 | 0 | 0.61 |
| Relapse (no versus yes) |
3 | 253 | FEM | 0.74 (0.36–1.5) | 0.4 | 0 | 0.72 |